[Ip-health] PhRMA Special 301 submission 2016

Shailly shailly.17 at gmail.com
Thu Feb 11 04:31:12 PST 2016


<https://donttradeourlivesaway.wordpress.com/author/donttradeourlivesaway/>
PhRMA
Special 301 submission 2016
<https://donttradeourlivesaway.wordpress.com/2016/02/11/phrma-special-301-submission-2016/>
by donttradeourlivesaway
<https://donttradeourlivesaway.wordpress.com/author/donttradeourlivesaway/>

https://donttradeourlivesaway.wordpress.com/2016/02/11/phrma-special-301-submission-2016/

PhRMA Special 301 Submission 2016 - India
<https://donttradeourlivesaway.files.wordpress.com/2016/02/phrma-special-301-submission-2016-india.pdf>
insists
that India remains on the Priority Watch List in the USTR Special 301
Report. PhRMA sees India’s progressive Patent Act of 2005 and IP
environment as a legal and regulatory barrier to patentability of newer
drugs. Also, it repeatedly pushes for the introduction of ‘Data
Exclusivity’. Import duties and taxation policy on pharmaceutical products,
drug price control policy and clinical research procedures PhRMA Special
301 Submission 2016 - India too have been highlighted as key issues of
concern.

The submission attempts to present that India’s IPR regime does not welcome
pharmaceutical innovations, thereby restricting the access to medicines for
Indian patients. PhRMA has high expectation from the draft IPR Policy and
is hoping that it will bring Indian IP rules closer to global standards
which will lead to foster innovation and investment.  Furthermore, PhRMA
urges USTR ‘to provide an opportunity for a meaningful assessment of
India’s IP regime through an Out-of-Cycle Review’, so that the U.S.
government can evaluate India’s working on IP issues and ‘dedicate the
required bilateral attention necessary to translate India’s commitment into
substantive and real policy change in the IP.


--------------

Shailly Gupta

+91-9899976108



More information about the Ip-health mailing list